Sitagliptin (BioDeep_00000017874)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(2R)-4-oxo-4-[3-(TRIFLUOROMETHYL)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine

化学式: C16H15F6N5O (407.11807319999997)
中文名称: 西他列汀消旋体, 西他列汀
谱图信息: 最多检出来源 Homo sapiens(blood) 33.33%

分子结构信息

SMILES: C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N
InChI: InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2

描述信息

Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

22 个代谢物同义名

(2R)-4-oxo-4-[3-(TRIFLUOROMETHYL)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; 4-oxo-4-(3-(Trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine; Monohydrate, sitagliptin monophosphate; monoPhosphate monohydrate, sitagliptin; Sitagliptin monophosphate monohydrate; Monohydrate, sitagliptin phosphate; Phosphate monohydrate, sitagliptin; Sitagliptin phosphate monohydrate; Anhydrous, sitagliptin phosphate; Phosphate anhydrous, sitagliptin; Sitagliptin phosphate anhydrous; Phosphate, sitagliptin; Sitagliptin Phosphate; rac-Sitagliptin; Sitagliptinum; Sitagliptine; Sitagliptina; Sitagliptin; Sitagliptan; MK-0431; Januvia



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. Cardiovascular diabetology. 2024 02; 23(1):56. doi: 10.1186/s12933-024-02149-7. [PMID: 38331780]
  • Neda Rasouli, Naji Younes, Alokananda Ghosh, Jeanine Albu, Robert M Cohen, Ralph A DeFronzo, Elsa Diaz, Laure Sayyed Kassem, José A Luchsinger, Janet B McGill, William I Sivitz, William V Tamborlane, Kristina M Utzschneider, Steven E Kahn. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes care. 2024 Jan; ?(?):. doi: 10.2337/dc23-1070. [PMID: 38211595]
  • M Sue Kirkman, Mark Tripputi, Heidi Krause-Steinrauf, Ionut Bebu, Hiba AbouAssi, Henry Burch, Elizabeth Duran-Valdez, Hermes Florez, W Timothy Garvey, Daniel S Hsia, Maamoun Salam, Rodica Pop-Busui. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes care. 2024 Jan; ?(?):. doi: 10.2337/dc23-1332. [PMID: 38194519]
  • R Patel, N Parmar, S P Palit, N Rathwa, R Begum. A novel combination of sitagliptin and melatonin ameliorates T2D manifestations: studies on experimental diabetic models. Journal of endocrinological investigation. 2023 Aug; 46(8):1597-1612. doi: 10.1007/s40618-023-02014-6. [PMID: 36692817]
  • Eiji Kutoh, Alexandra N Kuto, Midori Akiyama, Eri Ozawa, Rumi Kurihara. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid. European journal of clinical pharmacology. 2023 Jul; 79(7):947-959. doi: 10.1007/s00228-023-03506-3. [PMID: 37193913]
  • Shigenori Hiruma, Fumika Shigiyama, Naoki Kumashiro. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study. Diabetes, obesity & metabolism. 2023 06; 25(6):1576-1588. doi: 10.1111/dom.15006. [PMID: 36749298]
  • Deborah J Wexler, Ian H de Boer, Alokananda Ghosh, Naji Younes, Ionut Bebu, Silvio E Inzucchi, Janet B McGill, Sunder Mudaliar, David Schade, Michael W Steffes, William V Tamborlane, Meng H Tan, Faramarz Ismail-Beigi. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA internal medicine. 2023 May; ?(?):. doi: 10.1001/jamainternmed.2023.1487. [PMID: 37213109]
  • D Jayabal, S Jayanthi, R Thirumalaisamy, R Karthika, Muhammad Nasir Iqbal. Comparative anti-Diabetic potential of phytocompounds from Dr. Duke's phytochemical and ethnobotanical database and standard antidiabetic drugs against diabetes hyperglycemic target proteins: an in silico validation. Journal of biomolecular structure & dynamics. 2023 Apr; ?(?):1-13. doi: 10.1080/07391102.2023.2187231. [PMID: 37011006]
  • Lijuan Zhang, Airong Chen, Jing Lu, Liuliu Ren, Zelin Hu. Effects of Sitagliptin on Metabolic Indices and Hormone Levels in Polycystic Ovary Syndrome: a Meta-analysis of Randomized Controlled Trials. Reproductive sciences (Thousand Oaks, Calif.). 2023 04; 30(4):1065-1073. doi: 10.1007/s43032-022-01061-3. [PMID: 35962305]
  • Hussam Hamza Sahib, Bassim Mohammad, Najah Rayish Hadi. Evaluation of anti-atherosclerotic effects of Sitagliptin via modulation of the mTOR pathway in male rabbits. Journal of medicine and life. 2023 Mar; 16(3):451-457. doi: 10.25122/jml-2022-0298. [PMID: 37168300]
  • Tomohiro Komatsu, Satomi Abe, Shihoko Nakashima, Kei Sasaki, Yasuki Higaki, Keijiro Saku, Shin-Ichiro Miura, Yoshinari Uehara. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells. Biomolecules. 2023 Jan; 13(2):. doi: 10.3390/biom13020228. [PMID: 36830597]
  • Roma Patel, Nishant Parmar, Nirali Rathwa, Sayantani Pramanik Palit, Yansui Li, Adolfo Garcia-Ocaña, Rasheedunnisa Begum. A novel therapeutic combination of sitagliptin and melatonin regenerates pancreatic β-cells in mouse and human islets. Biochimica et biophysica acta. Molecular cell research. 2022 08; 1869(8):119263. doi: 10.1016/j.bbamcr.2022.119263. [PMID: 35364117]
  • Qinghe Meng, Oleg G Chepurny, Colin A Leech, Napat Pruekprasert, Megan E Molnar, James Jason Collier, Robert N Cooney, George G Holz. The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice. Diabetes, obesity & metabolism. 2022 07; 24(7):1255-1266. doi: 10.1111/dom.14693. [PMID: 35293666]
  • Shu-Tong Zhou, Wen Cui, Li Kong, Xun Yang. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. Current medical science. 2022 Jun; 42(3):513-519. doi: 10.1007/s11596-022-2573-9. [PMID: 35451807]
  • Rashmi Pathak, Avinash Kumar, Henry A Palfrey, Kirsten P Stone, Narayan R Raju, Thomas W Gettys, Subramanyam N Murthy. Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2022 Jun; 71(5-6):711-722. doi: 10.1007/s00011-022-01572-4. [PMID: 35578028]
  • Jinmiao Lu, Lu Wang, Sufeng Zhou, Chen Zhou, Lijun Xie, Juan Chen, Dong Tang, Xusheng Tian, Daosheng Xie, Juping Ding, Tong Wang, Qiang Yu, Jinsong Ding, Feng Shao. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin. British journal of clinical pharmacology. 2022 06; 88(6):2946-2958. doi: 10.1111/bcp.15209. [PMID: 34965609]
  • Simon Thonsgaard, Timothy C R Prickett, Lasse H Hansen, Nicolai J Wewer Albrechtsen, Ulrik Ø Andersen, Dijana Terzic, Peter Plomgaard, Finn Gustafsson, Jens P Goetze, Peter D Mark. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men. Clinical chemistry. 2022 05; 68(5):713-720. doi: 10.1093/clinchem/hvac005. [PMID: 35175317]
  • Li-Da Wu, Nan Zhou, Jin-Yu Sun, Hao Yu, Ru-Xing Wang. Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis. Journal of cardiovascular medicine (Hagerstown, Md.). 2022 05; 23(5):308-317. doi: 10.2459/jcm.0000000000001270. [PMID: 35486682]
  • Mao Yang, Ningning Xi, Meng Gao, Yanwei Yu. Sitagliptin mitigates hypoxia/reoxygenation (H/R)-induced injury in cardiomyocytes by mediating sirtuin 3 (SIRT3) and autophagy. Bioengineered. 2022 05; 13(5):13162-13173. doi: 10.1080/21655979.2022.2074109. [PMID: 35635037]
  • Reham Hussein Mohamed, Amina Ahmed Sedky, Ghada Galal Hamam, Lobna Elkhateb, Sherif A Kamar, Seham Adel, Sherin Shafik Tawfik. Sitagliptin's renoprotective effect in a diabetic nephropathy model in rats: The potential role of PI3K/AKT pathway. Fundamental & clinical pharmacology. 2022 Apr; 36(2):324-337. doi: 10.1111/fcp.12736. [PMID: 34735026]
  • Ping Shi, Xin Liu, Ting Li, Fei-Fei Sun, Yan-Ping Liu, Shu-Qin Liu, Xiao-Meng Gao, Ya-Ping Ma, Yao Fu, Yu Cao. Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study. Drugs in R&D. 2022 Mar; 22(1):15-23. doi: 10.1007/s40268-021-00371-2. [PMID: 34850368]
  • Delbar Daneshjou, Malek Soleimani Mehranjani, Shahrzad Zadehmodarres, Seyed Mohammad Ali Shariatzadeh, Zahra Shams Mofarahe. Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial). Journal of reproductive immunology. 2022 Mar; 150(?):103499. doi: 10.1016/j.jri.2022.103499. [PMID: 35217236]
  • Andrea Tura, Christian Göbl, Irfan Vardarli, Giovanni Pacini, Michael Nauck. Insulin clearance and incretin hormones following oral and 'isoglycemic' intravenous glucose in type 2 diabetes patients under different antidiabetic treatments. Scientific reports. 2022 02; 12(1):2510. doi: 10.1038/s41598-022-06402-5. [PMID: 35169165]
  • Lina Lin, Liman Wang. Knockdown of DPP4 promotes the proliferation and the activation of the CREB/aromatase pathway in ovarian granulosa cells. Molecular medicine reports. 2022 Feb; 25(2):. doi: 10.3892/mmr.2022.12589. [PMID: 35014677]
  • Elisha Ngetich, Pierfrancesco Lapolla, Anirudh Chandrashekar, Ashok Handa, Regent Lee. The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review. Vascular medicine (London, England). 2022 02; 27(1):77-87. doi: 10.1177/1358863x211034574. [PMID: 34392748]
  • Vera M Kosman, Marina V Karlina, Natalia M Faustova, Valery G Makarov, Marina N Makarova. Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin. Biopharmaceutics & drug disposition. 2022 Feb; 43(1):3-10. doi: 10.1002/bdd.2305. [PMID: 34724222]
  • Yunting Zhou, Huiying Wang, Yuming Wang, Xiaohua Xu, Fengfei Li, Junming Zhou, Ting Shan, Rong Huang, Tingting Cai, Xiaomei Liu, Xiaofei Su, Huiqin Li, Jianhua Ma. Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes. Frontiers in endocrinology. 2022; 13(?):801271. doi: 10.3389/fendo.2022.801271. [PMID: 35547000]
  • Natalia McInnes, Stephanie Hall, Irene Hramiak, Ronald J Sigal, Ronald Goldenberg, Nikhil Gupta, Remi Rabasa-Lhoret, Manoela Braga, Vincent Woo, Farah Sultan, Rose Otto, Ada Smith, Diana Sherifali, Yan Yun Liu, Hertzel C Gerstein, Natalia McInnes, Hertzel C Gerstein, Stephanie Hall, Stephanie Blanchard, Nikki Pinder, Yan Yun Liu, Natalia McInnes, Farah Sultan, Rose Otto, Ada Smith, Diana Sherifali, Hertzel C Gerstein, Irene Hramiak, Terri Paul, Tisha Joy, Margaret Watson, Marsha Driscoll, Ronald Sigal, Sonia Butalia, Brittany Rossiter, Michelle Smith, Victoria Tully, Ronald Goldenberg, Nikhil Gupta, Robert Schlosser, David Sionit, Tanvi Talsania, Jennifer Huynh, Sarah Birch, Sukaina Davdani, Remi Rabasa-Lhoret, Danijela Bovan, Marie Raffray, Manoela Braga, Natalia McInnes, Ada Smith, Tracy Tazzeo, Rose Otto, Kelly Scott, Katie Hiltz Mackenzie, Vincent Woo, Lori Berard, Claudia Mandock, Theresa Anderlic. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Diabetes care. 2022 01; 45(1):178-185. doi: 10.2337/dc21-0278. [PMID: 34728531]
  • Qizhi Tang, Weiyu Pan, Liangyue Peng. The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in endocrinology. 2022; 13(?):962385. doi: 10.3389/fendo.2022.962385. [PMID: 36060938]
  • Xingchun Wang, Bangfeng Zhao, Hang Sun, Hui You, Shen Qu. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease. Frontiers in endocrinology. 2022; 13(?):866189. doi: 10.3389/fendo.2022.866189. [PMID: 36072931]
  • Hayder M Al-Kuraishy, Ali I Al-Gareeb, Naeem Qusty, Athanasios Alexiou, Gaber El-Saber Batiha. Impact of Sitagliptin on Non-diabetic Covid-19 Patients. Current molecular pharmacology. 2022; 15(4):683-692. doi: 10.2174/1874467214666210902115650. [PMID: 34477540]
  • Xiaojing Zhang, Baoyi Zhu, Peibin Lin, Xiaoping Liu, Jun Gao, Dazhong Yin, Jianwen Zeng, Baojian Liao, Zhanfang Kang. Niacin exacerbates β cell lipotoxicity in diet-induced obesity mice through upregulation of GPR109A and PPARγ2: Inhibition by incretin drugs. Frontiers in endocrinology. 2022; 13(?):1057905. doi: 10.3389/fendo.2022.1057905. [PMID: 36568082]
  • Liang Xu, Fengmin Shao. Sitagliptin protects renal glomerular endothelial cells against high glucose-induced dysfunction and injury. Bioengineered. 2022 01; 13(1):655-666. doi: 10.1080/21655979.2021.2012550. [PMID: 34967261]
  • Yingze Liu, Xiangjun Meng, Yuyao Zhang, Linge Zhang, Yuqin Shan, Jingkai Gu, Dong Sun. High-throughput bioanalysis of sitagliptin in plasma using direct analysis in real time mass spectrometry and its application in the pharmacokinetic study thereof. Journal of separation science. 2022 Jan; 45(2):631-637. doi: 10.1002/jssc.202100461. [PMID: 34709732]
  • Suzan A Khodir, Manar A Faried, Huda I Abd-Elhafiz, Eman M Sweed. Sitagliptin Attenuates the Cognitive Deficits in L-Methionine-Induced Vascular Dementia in Rats. BioMed research international. 2022; 2022(?):7222590. doi: 10.1155/2022/7222590. [PMID: 35265716]
  • Wadhah Atef Salem, Ehab Farouk Elkady, Marwa Ahmed Fouad, Mohammad Abdul-Azim Mohammad. Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization. Journal of AOAC International. 2021 Dec; 104(6):1667-1680. doi: 10.1093/jaoacint/qsab106. [PMID: 34410406]
  • Mohsin Kazi, Abdulmohsen Alqahtani, Ajaz Ahmad, Omar M Noman, Mohammed S Aldughaim, Ali S Alqahtani, Fars K Alanazi. Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. Drug delivery. 2021 Dec; 28(1):100-114. doi: 10.1080/10717544.2020.1859001. [PMID: 33345632]
  • Bryanne Silva Figueiredo, Francielle Batista D Ferreira, Amanda Marreiro Barbosa, Cristiane Dos Santos, Henrik Ortsäter, Alex Rafacho. Coadministration of sitagliptin or metformin has no major impact on the adverse metabolic outcomes induced by dexamethasone treatment in rats. Life sciences. 2021 Dec; 286(?):120026. doi: 10.1016/j.lfs.2021.120026. [PMID: 34627773]
  • Maha H Sharawy, Dalia H El-Kashef, Ahmed A Shaaban, Dina S El-Agamy. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition. International immunopharmacology. 2021 Nov; 100(?):108088. doi: 10.1016/j.intimp.2021.108088. [PMID: 34454288]
  • Miranda F Kamal, Samir Morshedy, Dina A Saad, Marwa S Moneeb. Second-derivative synchronous fluorimetry and time-programmed HPLC-fluorescence detection for simultaneous estimation of flibanserin and sitagliptin phosphate in synthetic mixtures and human plasma samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2021 Nov; 1184(?):122955. doi: 10.1016/j.jchromb.2021.122955. [PMID: 34653844]
  • Ping Li, Lin-Lang Liang, Yu Wang, Da Hou, Xin Yang, Bo Yang. [Effects of Metformin and Sitagliptin on islet cell function in insulin-resistant prediabetic KKay mice]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology. 2021 Nov; 37(6):644-649. doi: 10.12047/j.cjap.6062.2021.084. [PMID: 34821099]
  • Dinghui Liu, Juan Pang, Weijuan Shao, Jianqiu Gu, Yong Zeng, Housheng Hansen He, Wenhua Ling, Xiaoxian Qian, Tianru Jin. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. Hepatology (Baltimore, Md.). 2021 10; 74(4):2154-2169. doi: 10.1002/hep.31856. [PMID: 33851458]
  • Chih-Pei Lin, Po-Hsun Huang, Chi-Yu Chen, Meng-Yu Wu, Jia-Shiong Chen, Jaw-Wen Chen, Shing-Jong Lin. Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice. Scientific reports. 2021 09; 11(1):17851. doi: 10.1038/s41598-021-97361-w. [PMID: 34497344]
  • Humaira Majeed Khan, Huma Nawaz, Huma Aerooj, Ali Sharif. Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination. Pakistan journal of pharmaceutical sciences. 2021 Sep; 34(5(Supplementary)):1939-1944. doi: ". [PMID: 34836863]
  • Dave L Dixon, Hayley E Billingsley, Justin M Canada, Cory R Trankle, Dinesh Kadariya, Richard Cooke, Linda Hart, Benjamin Van Tassell, Antonio Abbate, Salvatore Carbone. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. Journal of cardiovascular pharmacology. 2021 09; 78(3):407-410. doi: 10.1097/fjc.0000000000001083. [PMID: 34132690]
  • Mark M Smits, Kristina S Fluitman, Hilde Herrema, Mark Davids, Mark H H Kramer, Albert K Groen, Clara Belzer, Willem M de Vos, Djuna L Cahen, Max Nieuwdorp, Daniël H van Raalte. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Diabetes & metabolism. 2021 09; 47(5):101223. doi: 10.1016/j.diabet.2021.101223. [PMID: 33429063]
  • Weiping Jia, Jianhua Ma, Heng Miao, Changjiang Wang, Xiaoyue Wang, Quanmin Li, Weiping Lu, Jialin Yang, Lihui Zhang, Jinkui Yang, Guixia Wang, Xiuzhen Zhang, Min Zhang, Li Sun, Xuefeng Yu, Jianling Du, Bingyin Shi, Changqing Xiao, Dalong Zhu, Hong Liu, Liyong Zhong, Chun Xu, Qi Xu, Ganxiong Liang, Ying Zhang, Guangwei Li, Mingyu Gu, Jun Liu, Guoyue Yuan, Zhaoli Yan, Dewen Yan, Shandong Ye, Fan Zhang, Zhiqiang Ning, Haixiang Cao, Desi Pan, He Yao, Xianping Lu, Linong Ji. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Science bulletin. 2021 08; 66(15):1581-1590. doi: 10.1016/j.scib.2021.02.027. [PMID: 36654287]
  • Jing Zhang, Xing-Kai Qian, Pei-Fang Song, Xiao-Dong Li, An-Qi Wang, Hong Huo, Jing-Chun Yao, Gui-Min Zhang, Li-Wei Zou. A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma. Analytical methods : advancing methods and applications. 2021 06; 13(24):2671-2678. doi: 10.1039/d1ay00415h. [PMID: 34036983]
  • Shuhei Kamada, Takeshi Namekawa, Kazuhiro Ikeda, Takashi Suzuki, Makoto Kagawa, Hideki Takeshita, Akihiro Yano, Koji Okamoto, Tomohiko Ichikawa, Kuniko Horie-Inoue, Satoru Kawakami, Satoshi Inoue. Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. Oncogene. 2021 06; 40(22):3899-3913. doi: 10.1038/s41388-021-01822-5. [PMID: 33972682]
  • Sanaa K Bardaweel, Rima Hajjo, Dima A Sabbah. Sitagliptin: a potential drug for the treatment of COVID-19?. Acta pharmaceutica (Zagreb, Croatia). 2021 Jun; 71(2):175-184. doi: 10.2478/acph-2021-0013. [PMID: 33151168]
  • Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A O'Neill, Samuel S Engel, Keith D Kaufman. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, obesity & metabolism. 2021 06; 23(6):1342-1350. doi: 10.1111/dom.14346. [PMID: 33565686]
  • Neha Deora, M M Sunitha, M Satyavani, N Harishankar, Mookambeswaran A Vijayalakshmi, Krishnan Venkataraman, Vijayalakshmi Venkateshan. Alleviation of diabetes mellitus through the restoration of β-cell function and lipid metabolism by Aloe vera (L.) Burm. f. extract in obesogenic WNIN/GR-Ob rats. Journal of ethnopharmacology. 2021 May; 272(?):113921. doi: 10.1016/j.jep.2021.113921. [PMID: 33588009]
  • Suvanjaa Sivalingam, Emil List Larsen, Daniel H van Raalte, Marcel H A Muskiet, Mark M Smits, Lennart Tonneijck, Jaap A Joles, Bernt Johan von Scholten, Emilie Hein Zobel, Frederik Persson, Trine Henriksen, Lars Jorge Diaz, Tine W Hansen, Henrik Enghusen Poulsen, Peter Rossing. The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Scientific reports. 2021 05; 11(1):10624. doi: 10.1038/s41598-021-90191-w. [PMID: 34012064]
  • Herbert Nar, Gisela Schnapp, Oliver Hucke, Timothy C Hardman, Thomas Klein. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. ChemMedChem. 2021 05; 16(9):1425-1426. doi: 10.1002/cmdc.202000921. [PMID: 33348462]
  • Delbar Daneshjou, Shahrzad Zadeh Modarres, Malek Soleimani Mehranjani, Seyed Mohammad Ali Shariat Zadeh. Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI. Irish journal of medical science. 2021 May; 190(2):685-692. doi: 10.1007/s11845-020-02320-5. [PMID: 32720198]
  • Hany H Arab, Amany M Gad, Enji Reda, Rania Yahia, Ahmed H Eid. Activation of autophagy by sitagliptin attenuates cadmium-induced testicular impairment in rats: Targeting AMPK/mTOR and Nrf2/HO-1 pathways. Life sciences. 2021 Mar; 269(?):119031. doi: 10.1016/j.lfs.2021.119031. [PMID: 33453244]
  • Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M Shimizu, Antonio C Seguro, Weverton M Luchi, Adriana C C Girardi. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD. American journal of physiology. Renal physiology. 2021 03; 320(3):F285-F296. doi: 10.1152/ajprenal.00288.2020. [PMID: 33346727]
  • Yuki Shimizu, Hiroshi Hara, Tohru Hira. Glucagon-like peptide-1 response to whey protein is less diminished by dipeptidyl peptidase-4 in comparison with responses to dextrin, a lipid and casein in rats. The British journal of nutrition. 2021 02; 125(4):398-407. doi: 10.1017/s0007114520002834. [PMID: 32713353]
  • Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovascular diabetology. 2021 02; 20(1):32. doi: 10.1186/s12933-021-01228-3. [PMID: 33530982]
  • Leslye Sámano-Hernández, Reyna Fierro, Aude Marchal, Jean-Louis Guéant, Humberto González-Márquez, Rosa-María Guéant-Rodríguez. Beneficial and deleterious effects of sitagliptin on a methionine/choline-deficient diet-induced steatohepatitis in rats. Biochimie. 2021 Feb; 181(?):240-248. doi: 10.1016/j.biochi.2020.12.004. [PMID: 33333172]
  • Wenjuan Liu, Harry Kevin Lau, Dong Ok Son, Tianru Jin, Yehong Yang, Zhaoyun Zhang, Yiming Li, Gerald J Prud'homme, Qinghua Wang. Combined use of GABA and sitagliptin promotes human β-cell proliferation and reduces apoptosis. The Journal of endocrinology. 2021 02; 248(2):133-143. doi: 10.1530/joe-20-0315. [PMID: 33258801]
  • Mazhar Hussain, Asim Elahi, Abid Hussain, Javed Iqbal, Lubna Akhtar, Abdul Majid. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes. Journal of diabetes research. 2021; 2021(?):9973862. doi: 10.1155/2021/9973862. [PMID: 34239940]
  • Sarah L Craig, Victor A Gault, Peter R Flatt, Nigel Irwin. The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin. Biochemical pharmacology. 2021 01; 183(?):114355. doi: 10.1016/j.bcp.2020.114355. [PMID: 33279496]
  • Flory T Muanda, Matthew A Weir, Lavanya Bathini, Kristin K Clemens, Vlado Perkovic, Manish M Sood, Eric McArthur, Jessica M Sontrop, Richard B Kim, Amit X Garg. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. Clinical journal of the American Society of Nephrology : CJASN. 2020 12; 15(12):1728-1739. doi: 10.2215/cjn.08310520. [PMID: 33239410]
  • Michael A Nauck, Juris J Meier. Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. Diabetes care. 2020 12; 43(12):2906-2909. doi: 10.2337/dci20-0062. [PMID: 33033068]
  • Niki Katsiki, Ele Ferrannini. Anti-inflammatory properties of antidiabetic drugs: A 'promised land' in the COVID-19 era?. Journal of diabetes and its complications. 2020 12; 34(12):107723. doi: 10.1016/j.jdiacomp.2020.107723. [PMID: 32900588]
  • Marco Mirani, Giuseppe Favacchio, Flaminia Carrone, Nazarena Betella, Emilia Biamonte, Emanuela Morenghi, Gherardo Mazziotti, Andrea Gerardo Lania. Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes care. 2020 12; 43(12):3042-3049. doi: 10.2337/dc20-1340. [PMID: 33023989]
  • Sebastiano Bruno Solerte, Francesca D'Addio, Roberto Trevisan, Elisabetta Lovati, Antonio Rossi, Ida Pastore, Marco Dell'Acqua, Elio Ippolito, Cristiana Scaranna, Rosalia Bellante, Silvia Galliani, Alessandro Roberto Dodesini, Giuseppe Lepore, Francesca Geni, Roberta Maria Fiorina, Emanuele Catena, Angelo Corsico, Riccardo Colombo, Marco Mirani, Carlo De Riva, Salvatore Endrio Oleandri, Reza Abdi, Joseph V Bonventre, Stefano Rusconi, Franco Folli, Antonio Di Sabatino, Gianvincenzo Zuccotti, Massimo Galli, Paolo Fiorina. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes care. 2020 12; 43(12):2999-3006. doi: 10.2337/dc20-1521. [PMID: 32994187]
  • Gabriel Onn Kit Loh, Emily Yii Ling Wong, Yvonne Tze Fung Tan, Yi Lin Lee, Lai Hui Pang, May Chien Chin, Nair Damenthi, Kok Khiang Peh. Simple and rapid LC-MS/MS method for determination of sitagliptin in human plasma and application to bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Nov; 1159(?):122337. doi: 10.1016/j.jchromb.2020.122337. [PMID: 32905988]
  • Kazumi Mori-Anai, Yoshihiko Tashima, Tomohisa Nakada, Yoshinobu Nakamaru, Takayuki Takahata, Ryuta Saito. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics. Biopharmaceutics & drug disposition. 2020 Nov; 41(8-9):352-366. doi: 10.1002/bdd.2253. [PMID: 33085977]
  • Meng-Meng Ning, Wen-Ji Yang, Wen-Bo Guan, Yi-Pei Gu, Ying Feng, Ying Leng. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Acta pharmacologica Sinica. 2020 Nov; 41(11):1446-1456. doi: 10.1038/s41401-020-0413-7. [PMID: 32398684]
  • Sherihan Salaheldin Abdelhamid Ibrahim, Mona Abdelrazek Salama, Eman Selima, Rowaida Refaat Shehata. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways. Life sciences. 2020 Nov; 260(?):118261. doi: 10.1016/j.lfs.2020.118261. [PMID: 32795539]
  • Xinran He, Wangen Li, Yunliang Xie, Yunjuan Zhao. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice. International immunopharmacology. 2020 Nov; 88(?):106945. doi: 10.1016/j.intimp.2020.106945. [PMID: 33182020]
  • Mahsa Rezaeepoor, Mirhamed Hoseini-Aghdam, Vida Sheikh, Mohammad Mahdi Eftekharian, Mahdi Behzad. Evaluation of Interleukin-23 and JAKs/STATs/SOCSs/ROR-γt Expression in Type 2 Diabetes Mellitus Patients Treated With or Without Sitagliptin. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2020 11; 40(11):515-523. doi: 10.1089/jir.2020.0113. [PMID: 33136467]
  • Sin Gon Kim, Kyoung Jin Kim, Kun Ho Yoon, Sung Wan Chun, Kyong Soo Park, Kyung Mook Choi, Soo Lim, Ji-Oh Mok, Hyoung Woo Lee, Ji A Seo, Bong-Soo Cha, Mi Kyung Kim, Ho Sang Shon, Dong Seop Choi, Doo Man Kim. Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. Diabetes, obesity & metabolism. 2020 10; 22(10):1869-1873. doi: 10.1111/dom.14085. [PMID: 32406573]
  • Negin Mozafari, Soha Azadi, Sanaz Mehdi-Alamdarlou, Hajar Ashrafi, Amir Azadi. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Medical hypotheses. 2020 Oct; 143(?):110111. doi: 10.1016/j.mehy.2020.110111. [PMID: 32721805]
  • Yi-Shan Li, Wei-Lung Tseng, Chi-Yu Lu. Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry. Talanta. 2020 Oct; 218(?):121143. doi: 10.1016/j.talanta.2020.121143. [PMID: 32797900]
  • Pascale Fouqueray, Sandrine Perrimond-Dauchy, Sébastien Bolze. Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. Clinical pharmacokinetics. 2020 10; 59(10):1261-1271. doi: 10.1007/s40262-020-00886-y. [PMID: 32270440]
  • Antonio Carlo Bossi, Valentina De Mori, Carlotta Galeone, Davide Pietro Bertola, Margherita Gaiti, Annalisa Balini, Denise Berzi, Franco Forloni, Giancarla Meregalli, Federica Turati. PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness. BMJ open diabetes research & care. 2020 09; 8(1):. doi: 10.1136/bmjdrc-2020-001507. [PMID: 32900698]
  • Shufeng Cheng, Liang Li, Chunquan Song, Huijing Jin, Shouguo Ma, Ping Kang. Sitagliptin relieves diabetic nephropathy fibrosis via the MAPK/ERK signaling pathway. Minerva endocrinologica. 2020 09; 45(3):273-275. doi: 10.23736/s0391-1977.20.03122-3. [PMID: 32077673]
  • Elodie M Varin, Antonio A Hanson, Jacqueline L Beaudry, My-Anh Nguyen, Xiemin Cao, Laurie L Baggio, Erin E Mulvihill, Daniel J Drucker. Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice. JCI insight. 2020 08; 5(16):. doi: 10.1172/jci.insight.140418. [PMID: 32663193]
  • M Maia Pinheiro, F Moura Maia Pinheiro, L L Pires Amaral Resende, S Nogueira Diniz, A Fabbri, M Infante. Improvement of pure sensory mononeuritis multiplex and IgG1 deficiency with sitagliptin plus Vitamin D3. European review for medical and pharmacological sciences. 2020 08; 24(15):8151-8159. doi: 10.26355/eurrev_202008_22502. [PMID: 32767343]
  • Clement Lo, Tadashi Toyama, Megumi Oshima, Min Jun, Ken L Chin, Carmel M Hawley, Sophia Zoungas. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane database of systematic reviews. 2020 07; 8(?):CD009966. doi: 10.1002/14651858.cd009966.pub3. [PMID: 32803882]
  • Laurie L Baggio, Elodie M Varin, Jacqueline A Koehler, Xiemin Cao, Yuliya Lokhnygina, Susanna R Stevens, Rury R Holman, Daniel J Drucker. Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. Nature communications. 2020 07; 11(1):3766. doi: 10.1038/s41467-020-17556-z. [PMID: 32724076]
  • Yuhan Zhang, Tian Cai, Junyu Zhao, Congcong Guo, Jinming Yao, Peng Gao, Jianjun Dong, Lin Liao. Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2020 Jul; 52(7):517-526. doi: 10.1055/a-1186-0841. [PMID: 32559768]
  • Seol Ju Moon, Kyung-Sang Yu, Min-Gul Kim. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men. Clinical therapeutics. 2020 06; 42(6):1047-1057. doi: 10.1016/j.clinthera.2020.04.005. [PMID: 32362346]
  • Qunzi Zhang, Li He, Yang Dong, Yang Fei, Jiejun Wen, Xiaomei Li, Jian Guan, Feng Liu, Ting Zhou, Ze Li, Ying Fan, Niansong Wang. Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2020 06; 34(6):7500-7519. doi: 10.1096/fj.201903038r. [PMID: 32281218]
  • Farzaneh Dastan, Atefeh Abedini, Shahram Shahabi, Arda Kiani, Ali Saffaei, Ahad Zare. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung. Iranian journal of allergy, asthma, and immunology. 2020 May; 19(S1):10-12. doi: 10.18502/ijaai.v19i(s1.r1).2849. [PMID: 32534505]
  • Naoko Tajima, Jun-Ichi Eiki, Taro Okamoto, Kotoba Okuyama, Masaru Kawashima, Samuel S Engel. Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials. Journal of diabetes investigation. 2020 May; 11(3):640-646. doi: 10.1111/jdi.13182. [PMID: 31743602]
  • Minchun Zhang, Rilu Feng, Jiang Yue, Cheng Qian, Mei Yang, Wei Liu, Christopher K Rayner, Jing Ma. Effects of Metformin and Sitagliptin Monotherapy on Expression of Intestinal and Renal Sweet Taste Receptors and Glucose Transporters in a Rat Model of Type 2 Diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2020 May; 52(5):329-335. doi: 10.1055/a-1135-9031. [PMID: 32252106]
  • Yuntao Liu, Feng Xu, Pan Jiang. Effect of sitagliptin on expression of skeletal muscle peroxisome proliferator-activated receptor γ coactivator-1α and irisin in a rat model of type 2 diabetes mellitus. The Journal of international medical research. 2020 May; 48(5):300060519885569. doi: 10.1177/0300060519885569. [PMID: 32364035]
  • Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Hayato Akimoto, Tomohiro Nakayama, Satoshi Asai. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus. BMC pharmacology & toxicology. 2020 04; 21(1):28. doi: 10.1186/s40360-020-00407-4. [PMID: 32317005]
  • Yue Sun, Dong Yan, Zirui Hao, Lijuan Cui, Guiping Li. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients. Medical science monitor : international medical journal of experimental and clinical research. 2020 Apr; 26(?):e921891. doi: 10.12659/msm.921891. [PMID: 32240122]
  • Neil Tanday, Peter R Flatt, Nigel Irwin, R Charlotte Moffett. Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes. The Journal of endocrinology. 2020 04; 245(1):53-64. doi: 10.1530/joe-19-0451. [PMID: 31977315]
  • Kyoko Tanimura-Inagaki, Mototsugu Nagao, Taro Harada, Hitoshi Sugihara, Shigeki Moritani, Jun Sasaki, Suminori Kono, Shinichi Oikawa. Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study. Diabetes research and clinical practice. 2020 Apr; 162(?):108119. doi: 10.1016/j.diabres.2020.108119. [PMID: 32194219]
  • Walaa Yehia Abdelzaher, Remon Roshdy Rofaeil, Doaa Mohamed Elroby Ali, Mina Ezzat Attya. Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion/detorsion in rats: a possible role of HIF-1α and nitric oxide. Naunyn-Schmiedeberg's archives of pharmacology. 2020 04; 393(4):603-614. doi: 10.1007/s00210-019-01765-5. [PMID: 31773182]
  • Vikas Taneja. Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease. Hepatology (Baltimore, Md.). 2020 03; 71(3):1128. doi: 10.1002/hep.30992. [PMID: 31610029]
  • Marieke Sternkopf, Magdolna Nagy, Constance C F M J Baaten, Marijke J E Kuijpers, Bibian M E Tullemans, Julia Wirth, Wendy Theelen, Tom G Mastenbroek, Michael Lehrke, Benjamin Winnerling, Lesley Baerts, Nikolaus Marx, Ingrid De Meester, Yvonne Döring, Judith M E M Cosemans, Andreas Daiber, Sebastian Steven, Joachim Jankowski, Johan W M Heemskerk, Heidi Noels. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. Arteriosclerosis, thrombosis, and vascular biology. 2020 03; 40(3):e65-e77. doi: 10.1161/atvbaha.119.313645. [PMID: 31893947]
  • Gaetano M De Ferrari, Susanna R Stevens, Giuseppe Ambrosio, Sergio Leonardi, Paul W Armstrong, Jennifer B Green, Malgorzata Wamil, Rury R Holman, Eric D Peterson. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. American heart journal. 2020 02; 220(?):82-88. doi: 10.1016/j.ahj.2019.11.005. [PMID: 31790905]